Eskild PETERSEN, Asma Al BALUSHI, Alimuddin ZUMLA, Deniz GÖKENGİN

One and a half years into the COVID-19 pandemic - exit strategies and efficacy of SARSCoV-2 vaccines for holistic management and achieving global control

Abstract: One and a half years into the pandemic, SARS-CoV-2 is still here to stay. Whilst rapid several effective COVID-19 vaccines have been developed and are being rolled out, the critical questions remain whether vaccines provide widespread protection against infection and reinfection, and what the duration of protection is. Community wide control cannot be obtained until almost everyone is immune. Vaccine production must be ramped up to cover the world population. The price of herd immunity through natural infection is high mortality in the elderly and morbidity in other age groups including children and Long-COVID. We must expect a new wave in the coming winter. The severity will depend on the proportion of the population with immunity from natural infections or immunisation. Therefore, control rests on a population wide immunisation including children, which may or may not need to be repeated if new SARSCoV-2 variants evolve that can escape immunity from either previous infections or immunisations. Preventing long term sequelae of COVID-19 also remains a priority.Key words: COVID-19, Vaccines, surveillance, zoonosis, variants

PDF

___

1. Fontanet A Cauchemez S. COVID-19 herd immunity: where are we? Nature Reviews of Immunology 2020; 20: 583-584. doi: 10.1038/s41577-020-00451-5
2. Sanyang B, Kanteh A, Usuf E, Nadjm B, Jarju S et al. COVID-19 reinfections in The Gambia by phylogenetically distinct SARSCoV-2 variants—first two confirmed events in west Africa. The Lancet Global Health 3 June 2021. doi:https://doi.org/10.1016/ S2214-109X(21)00213-8
3. Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A et al. The implications of silent transmission for the control of COVID-19 outbreak. Proceedings of the National Academy of Science USA. 2020; 117: 17513–17515. doi: 10.1073/ pnas.2008373117
4. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infectious Diseases 2020; 20(9): e238-e244. doi: 10.1016/S1473-3099(20)30484-9
5. Petersen E, Buchy P. Vaccination against SARS-CoV-2 should be included in childhood vaccination programs. International Journal of Infectious Diseases 2021;106:429-430. doi: 10.1016/j. ijid.2021.04.082
6. Piroth L, Cottenet J, Mariet A-S, Bonniaud P, Blot M et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, populationbased retrospective cohort study. Lancet Respiratory Medicine 2020; 9(3): 251-259. doi: 10.1016/S2213-2600(20)30527-0
7. Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L et al. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccines. Science Immunology 2021; 6(59): eabj1750. doi:10.1126/sciimmunol.abj1750
8. Milman O, Yelin I, Aharony N, Katz R, Herzel E et al. Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals. Nature Medicine 2021 10th June. doi: 10.1038/s41591-021-01407-5
9. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 2020; 368(6493): 860-868. doi: 10.1126/science.abb5793
10. Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the transition of COVID-19 to endemicity. Science 2021: 371 (6530): 741-745. doi.10.1126/ science.abe6522
11. Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nature Medicine 2021 July 9th. doi: 10.1038/ s41591-021-01446-y. Online ahead of print.
12. Thompson MG, Burgess JL, Naleway AL, et al. Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med 2021;385:320–9. PMID:34192428.
13. Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight U.S. locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep 2021;70:495–500.
14. Tanriover MD, Doganay HL, Akova M, Güner HR, Azap A et al. Eðcacy and safety of an inactivated whole-virion SARSCoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet 2021 July 8, https://doi.org/10.1016/ S0140- 6736(21)01429-X
15. Jara A, Undurraga EA, González C, Paredes F, Fontecilla F et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. New England Journal of Medicine 2021, 7th July. doi: 10.1056/ NEJMoa2107715
16. Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, et al. Effectiveness of COVID-19 Vaccines in Preventing SARSCoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 202. MMWR 2021 70(34):1167-69.
17. Phelan AL, Eccleston-Turney M, Rourke M, Maleche A, Wang C. Legal agreements: barriers and enablers to global equitable COVID-19 vaccine access. Lancet 2020; 396(10254): 800–802. doi: 10.1016/S0140-6736(20)31873-0
18. Fidler DP. Negotiating equitable access to influenza vaccines: global health diplomacy and the controversies surrounding avian influenza H5N1 and pandemic influenza H1N1. PLoS Medicine. 2010; 7(5): e1000247. doi: 10.1371/journal. pmed.1000247
19. Castillo JC, Ahuja A, Athey S, Baker A, Budish E et al. Market design to accelerate COVID-19 vaccine supply. Science 2021; 371(6534): 1107-1109. doi: 10.1126/science.abg0889
20. Schwabenland M, Salié H, Tanevski J, Killmer S, Lago MS et al. Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T cell interactions. Cell 2021; 9th June. doi:https:// doi.org/10.1016/j.immuni.2021.06.002
21. Rasmussen TB, Fonager J, Jørgensen CS, Lassaunière R, Hammer AS et al. Infection, recovery and re-infection of farmed mink with SARS-CoV-2. bioRxiv preprint 7 May 2021. doi: https://doi.org/10.1101/2021.05.07.443055
22. Koopmans MK. SARS-CoV-2 and the human-animal interface: outbreaks on mink farms. Lancet Infectious Diseases 2021; 21(1) :18-19. doi.org/10.1016/ S1473-3099(20)30912-9
23. Xiao X, Newman C, Buesching CD, Macdonald DW, Zhou, Z-M. Animal sales from Wuhan wet markets immediately prior to the COVID-19 pandemic. Science Reports 2021; 11 (11898). doi.org/10.1038/s41598-021-91470-2
24. Zimmer SM, Burke DS. Historical perspective--Emergence of influenza A (H1N1) viruses. New England Journal of Medicine 2009; 361(3): 279-285. doi: 10.1056/NEJMra0904322